12.15 0.06 (0.5%) | 07-03 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 14.79 | 1-year : | 15.96 |
Resists | First : | 12.66 | Second : | 13.67 |
Pivot price | 12.07 ![]() |
|||
Supports | First : | 11.03 | Second : | 9.18 |
MAs | MA(5) : | 11.92 ![]() |
MA(20) : | 12.38 ![]() |
MA(100) : | 13.1 ![]() |
MA(250) : | 11.4 ![]() |
|
MACD | MACD : | -0.3 ![]() |
Signal : | -0.3 ![]() |
%K %D | K(14,3) : | 43.3 ![]() |
D(3) : | 36.2 ![]() |
RSI | RSI(14): 47.9 ![]() |
|||
52-week | High : | 16.9 | Low : | 5.84 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MLYS ] has closed below upper band by 45.7%. Bollinger Bands are 39.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 12.41 - 12.46 | 12.46 - 12.51 |
Low: | 11.87 - 11.93 | 11.93 - 11.98 |
Close: | 12.05 - 12.14 | 12.14 - 12.23 |
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Thu, 04 Jul 2024
Critical Contrast: Affimed (NASDAQ:AFMD) vs. Mineralys Therapeutics (NASDAQ:MLYS) - Defense World
Wed, 26 Jun 2024
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 6.7% - MarketBeat
Fri, 21 Jun 2024
Insider Sale: Eric Shander Sells 4,797 Shares of PowerSchool Holdings Inc (PWSC) By GuruFocus - Investing.com Canada
Fri, 14 Jun 2024
Mineralys Therapeutics Appoints Dr. Alexander Gold to Board Amid Hypertension Drug Development - MyChesCo
Fri, 14 Jun 2024
Mineralys Therapeutics Appoints Alexander M. Gold, M.D. To Board - citybiz
Fri, 14 Jun 2024
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 50 (M) |
Shares Float | 23 (M) |
Held by Insiders | 2.8 (%) |
Held by Institutions | 95.9 (%) |
Shares Short | 905 (K) |
Shares Short P.Month | 950 (K) |
EPS | -2.19 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 6.61 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -20.1 % |
Return on Equity (ttm) | -29.2 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -88 (M) |
Levered Free Cash Flow | -54 (M) |
PE Ratio | -5.58 |
PEG Ratio | -0.1 |
Price to Book value | 1.83 |
Price to Sales | 0 |
Price to Cash Flow | -6.9 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |